Dynagen signs tuberculosis (TB) licence with Remel:
This article was originally published in Clinica
Remel is to manufacture and sell Dynagen's MycoAKT TB typing tests in the US. The deal signed by the two companies gives Remel exclusive rights to the US market and non-exclusive rights for the rest of the world. MycoAKT is a latex agglutination test for identifying MTB complex, M avium complex and M kansasi in cultured samples. Around 5 million mycobacteria cultures are performed every year in the US.